65,000 Shares in Hims & Hers Health, Inc. (NYSE:HIMS) Bought by JW Asset Management LLC

JW Asset Management LLC purchased a new stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS) during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 65,000 shares of the company’s stock, valued at approximately $1,312,000. Hims & Hers Health accounts for about 0.5% of JW Asset Management LLC’s portfolio, making the stock its 11th biggest position.

Several other large investors have also made changes to their positions in the business. Nisa Investment Advisors LLC boosted its position in shares of Hims & Hers Health by 679.2% during the second quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock worth $37,000 after acquiring an additional 1,603 shares during the last quarter. Quest Partners LLC lifted its stake in Hims & Hers Health by 5,944.1% in the 2nd quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock worth $72,000 after purchasing an additional 3,507 shares in the last quarter. Van ECK Associates Corp bought a new position in shares of Hims & Hers Health during the 2nd quarter valued at about $111,000. Daiwa Securities Group Inc. purchased a new position in shares of Hims & Hers Health during the second quarter valued at about $142,000. Finally, DekaBank Deutsche Girozentrale purchased a new position in shares of Hims & Hers Health during the second quarter valued at about $143,000. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Hims & Hers Health

In other Hims & Hers Health news, CEO Andrew Dudum sold 188,888 shares of the firm’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $14.56, for a total transaction of $2,750,209.28. Following the transaction, the chief executive officer now directly owns 33,502 shares in the company, valued at approximately $487,789.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, COO Melissa Baird sold 11,749 shares of the company’s stock in a transaction that occurred on Wednesday, September 4th. The shares were sold at an average price of $14.65, for a total value of $172,122.85. Following the completion of the sale, the chief operating officer now owns 585,800 shares of the company’s stock, valued at approximately $8,581,970. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Andrew Dudum sold 188,888 shares of Hims & Hers Health stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $14.56, for a total transaction of $2,750,209.28. Following the transaction, the chief executive officer now directly owns 33,502 shares in the company, valued at $487,789.12. The disclosure for this sale can be found here. Over the last three months, insiders have sold 753,292 shares of company stock valued at $13,557,329. 17.71% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of brokerages recently commented on HIMS. Citigroup lowered Hims & Hers Health from a “buy” rating to a “neutral” rating and increased their price target for the company from $16.00 to $20.00 in a research note on Wednesday, May 22nd. Imperial Capital downgraded Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research report on Friday, August 9th. TD Cowen boosted their price target on shares of Hims & Hers Health from $15.00 to $25.00 and gave the stock a “buy” rating in a research report on Thursday, July 11th. Canaccord Genuity Group increased their price objective on shares of Hims & Hers Health from $20.00 to $24.00 and gave the company a “buy” rating in a research report on Wednesday, May 22nd. Finally, Needham & Company LLC started coverage on shares of Hims & Hers Health in a report on Thursday, August 22nd. They issued a “buy” rating and a $24.00 target price on the stock. Eight analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $19.86.

Hims & Hers Health Stock Performance

Shares of NYSE HIMS opened at $16.57 on Friday. Hims & Hers Health, Inc. has a fifty-two week low of $5.65 and a fifty-two week high of $25.74. The company has a market cap of $3.56 billion, a price-to-earnings ratio of -1,657.00 and a beta of 1.05. The business’s 50 day moving average price is $17.80 and its 200-day moving average price is $16.98.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, August 5th. The company reported $0.06 earnings per share for the quarter, topping the consensus estimate of $0.04 by $0.02. The business had revenue of $315.65 million during the quarter, compared to the consensus estimate of $302.43 million. Hims & Hers Health had a return on equity of 5.25% and a net margin of 1.70%. The business’s revenue for the quarter was up 51.8% compared to the same quarter last year. During the same period last year, the company earned ($0.03) earnings per share. Sell-side analysts predict that Hims & Hers Health, Inc. will post 0.22 earnings per share for the current year.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.